{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:17:06Z","timestamp":1759936626606},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.2169\/internalmedicine.1280-18","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T22:22:38Z","timestamp":1536704558000},"page":"585-591","source":"Crossref","is-referenced-by-count":6,"title":["Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept"],"prefix":"10.2169","volume":"58","author":[{"given":"Akio","family":"Kawabe","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Miyata","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Shibuya","sequence":"additional","affiliation":[{"name":"The Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuji","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"The Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ogoshi","sequence":"additional","affiliation":[{"name":"The Department of Respiratory Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98: 280-286, 2001.","DOI":"10.1182\/blood.V98.2.280"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 191: 531-539, 2005.","DOI":"10.1086\/427239"},{"key":"3","unstructured":"3. Quintanilla-Martinez L, Ko YH, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Eds. International Agency for Research on Cancer, Lyon, 2017: 355-362."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80: 64-69, 2005.","DOI":"10.1002\/ajh.20398"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Arai A, Imadome K, Watanabe Y, et al. Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol 93: 602-609, 2011.","DOI":"10.1007\/s12185-011-0831-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Isobe Y, Aritaka N, Setoguchi Y, et al. T\/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T\/NK-cell lymphoma. J Clin Pathol 65: 278-282, 2012.","DOI":"10.1136\/jclinpath-2011-200523"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65: 1667-1669, 2006.","DOI":"10.1136\/ard.2006.054197"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamashita H, Shimizu A, Tsuchiya H, et al. Chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis exacerbation in a patient with systemic lupus erythematosus. Lupus 23: 833-836, 2014.","DOI":"10.1177\/0961203314527367"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Balandraud N, Meynard JB, Auger I, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 48: 1223-1228, 2003.","DOI":"10.1002\/art.10933"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013.","DOI":"10.1111\/ejh.12116"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bartels CM, Bridges AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments? Curr Rheumatol Rep 12: 414-419, 2010.","DOI":"10.1007\/s11926-010-0130-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 13: 873-879, 2014.","DOI":"10.1016\/j.autrev.2014.05.005"},{"key":"13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"13. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, Version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14: 882-913, 2016.","DOI":"10.6004\/jnccn.2016.0093"},{"key":"15","unstructured":"15. Quintanilla-Martinez L, Ko YH, Kimura H, Jaffe ES. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Eds. International Agency for Research on Cancer, Lyon, 2017: 462-464."},{"key":"16","unstructured":"16. Dalal RS, LeGolvan MP, Stachurski DR, Goldberg LR. Epstein-Barr virus associated hemophagocytic lymphohistiocytosis in a rheumatic patient receiving abatacept therapy. R I Med J 97: 28-31, 2014."},{"key":"17","unstructured":"17. Bassil N, Rostaing L, Mengelle C, et al. Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant. Exp Clin Transplant 12: 212-219, 2014."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 57: 762-767, 2007.","DOI":"10.1002\/art.22783"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Balandraud N, Texier G, Massy E, et al. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study. PLoS One 12: e0171623, 2017.","DOI":"10.1371\/journal.pone.0171623"},{"key":"20","unstructured":"20. The Japan College of Rheumatology. Tocilizumab use guidelines for rheumatoid arthritis (RA) (2017 Revised Edition). [Internet]. [cited 2017 Nov. 29]. Available from: http:\/\/www.ryumachi-jp.com\/info\/guideline_tcz.pdf (in Japanese)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1280-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T04:45:23Z","timestamp":1550292323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1280-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1280-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}